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Opioid use disorders, including heroin use disorders, account for 70% 
of the global burden of drug-related disease[1] and disproportionately 
affect people who have unmet social, emotional, economic, health 
and other needs.[2,3] Heroin is widely available in South Africa (SA)[4,5] 
and there is an upward trend in numbers of people using heroin who 
access drug use treatment facilities registered with the South African 
Community Epidemiology Network on Drug Use.[6] In addition, 
there is increasing concern around the link between injecting heroin 
use, hepatitis C virus (HCV) and HIV and the impact this could have 
on SA communities and the healthcare system.[7]
Opioid substitution therapy (OST), using an agonist or partial 
agonist, aims to alleviate the symptoms of opioid withdrawal, reduce 
cravings, and reduce the opioid response through receptor coverage. 
Over 40 years of research has shown that OST saves lives,[8-11] improves 
retention in healthcare and treatment,[12-17] reduces illicit heroin 
use,[12,13,17,18] reduces interactions with the criminal justice system,[11,18,19] 
reduces HIV risk[20-22] and improves health and quality of life.[23-27]
Despite the increasing need and inclusion in the SA National 
Strategic Plan for HIV, TB and STIs (2017 - 2021),[7] none of the 
medications suitable for OST are listed on the Essential Drugs List 
(EDL) for maintenance prescribing. Methadone in SA is significantly 
more expensive than in other middle-income countries; for example, 
it costs up to 30 times more than the average cost in the Ukraine and 
Georgia.[28] The high cost of methadone makes it unattainable for the 
majority of South Africans who need it.
The Sultan Bahu Centre in Cape Town was the first civil society 
organisation to provide OST, doing so for 3 months as part of an 
intensive outpatient offering. Since 2016, financed mainly by foreign 
donors, the Durban University of Technology, TB HIV Care and 
the Anova Health Institute have started providing OST to a small 
number of people who use heroin in Durban, Cape Town and 
Johannesburg. [29] Since 2017, the City of Tshwane has funded OST as 
part of the community-orientated substance use programme run by 
the University of Pretoria.[31] For the most part, however, people in SA 
who have a heroin use disorder view OST as an important service that 
is unaffordable and inaccessible.[30]
In view of the need for OST and growing local experience, we 
facilitated a half-day workshop at the 2017 South African Drug 
Policy Week to develop an advocacy agenda for OST in SA. 
Participants included academics (n=6), OST prescribers (n=3), 
co-ordinators from ongoing OST projects (n=5), OST outreach staff 
(n=6), and representatives from the Western Cape Government 
(n=3), the pharmaceutical industry (n=3) and the people who use 
drugs (PWUD) community (n=2). Using the nominal group voting 
technique, research, policy, service delivery and collaborations were 
identified as OST advocacy priorities.
Research. Conducting research and economic evaluations on OST 
in SA’s service delivery context, applying for funding, the publication 
of findings from local demonstration projects and documentation of 
changes in the quality of life of people on OST were seen as essential. 
Epidemiology and surveillance of opioid use disorders, the burden 
of illicit opioid use, and the possible impact of OST on the health 
sector and the economy were suggested as considerations for a future 
research agenda. Youth and women were also noted as important 
areas for research.
Policy. Inclusion of OST in the 2018 - 2022 National Drug Master 
Plan, inclusion of medications for OST (specifically methadone 
and buprenorphine/buprenorphine-naloxone) on the EDL for OST 
as maintenance at the primary care level, and decriminalisation 
of people who use substances listed as illicit in SA law (although 
the third item was unlikely to be achieved in the short term) were 
considered the main policy advocacy objectives.
Service delivery. Participants voted to prioritise the integration of 
OST into current civil society services as a move towards providing 
the World Health Organization’s recommended package of services 
for people who inject drugs, inclusive of needle and syringe services, 
HIV and HCV prevention, testing and treatment services, and 
tuberculosis services,[31] as well as management of minor wounds and 
common comorbidities, including non-communicable diseases, and 
access to voluntary psychosocial services. Ultimately these services, 
including OST, should become part of the public and private health 
service at all levels of care in urban and rural areas. The need for 
low-threshold services, paralegal support services and reduced costs 
was also discussed.
Collaborations and networks. Participants prioritised the 
establish ment of a multisectoral OST advocacy group to lead 
advocacy efforts, the establishment of a website or Facebook page 
for sharing and accessing information, for publications and for 
networking, and the importance of the use of a common language 
for advocacy efforts. Funding was seen as critical to achieving these 
objectives. A mapping exercise identified other potential advocacy 
partners including clinician societies and associations, the South 
African National Council on Alcoholism and Drug Dependence, 
the Human Rights Commission, the various legal aid groups, and 
social movement organisations that mobilise around vulnerable 
groups. Unlikely partners such as the police, media, religious leaders 
and representatives from industry were viewed as vital actors in 
carving out an effective, sustained and recognised OST advocacy and 
implementation agenda.
The participants in the meeting identified a set of priority OST 
advocacy recommendations for SA:
• The National Drug Master Plan currently encourages harm 
reduction strategies as a means of caring for individuals already 
dependent on substances. The provision and support of OST by 
the National Department of Health (NDoH) would solidify this 
commitment to harm reduction. It would also go a long way 
to improving the health and social outcomes and prognosis of 
people with opioid use disorders, their families and the broader 
communities affected by drug use.
• The NDoH should be encouraged to develop and implement 
policies and practice conventions that allow for the safe prescribing 
and dispensing of OST in the public health sector at all levels of 
care. OST outcomes are best when its implementation is regulated, 
monitored and easily accessible. 
• Advocates need to engage with the NDoH Essential Drugs 
List Committee to incorporate OST medications as a form of 
maintenance treatment for use at the primary level of care.
• Researchers, service providers and other civil society organisations 
are encouraged to disseminate findings and lessons learnt related 
to OST interventions and research. The availability of local data 
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will encourage and improve current debate and general awareness 
regarding OST in this country. The media are critical to achieving 
such public awareness.
• OST advocacy networks and organisations currently providing 
OST services should actively engage the public through open 
debate around the effectiveness of these medications.
• The costs associated with opioid substitution medications currently 
restrict availability to a small percentage of South Africans. 
Stakeholders (state and non-state) should work collectively to 
ensure that prices are reduced and that OST medication is made 
more affordable and accessible.
• OST advocacy efforts must be network based. Partners in 
these networks should include police, professional bodies, civic 
organisations, harm reduction service providers, PWUD and 
their communities. ‘Whole of society’ networks would have the 
capacity to reduce stigma and enable people who use heroin to 
access services.
Access to OST is a human right. People affected by opioid use 
disorders are marginalised and stigmatised, and it is critical that an 
advocacy network and agenda be established to give voice to this 
community. Further, we feel that it is important to map out a feasible 
way to roll out OST, an intervention that has been proven globally 
to be effective. While OST and other harm reduction programmes 
are currently only operational in the non-government sector, harm 
reduction is embedded (implicitly or explicitly) in key drug control 
and treatment legislation. It is time to align drug-related policies 
and to implement harm reduction interventions as promulgated 
in our existing progressive health-orientated legislation. Devising 
processes and institutional arrangements for making OST available 
in the public and private sector is essential if we wish to curtail what 
currently appears to be an emerging heroin use pandemic. Action is 
also required if we want to avoid the further marginalisation of an 
already excluded group of people.
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